Company news

Cocrystal Pharma, Inc. news in 2026

Cocrystal Pharma, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment

September 9, 2026

Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors

August 17, 2026

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

August 3, 2026

Cocrystal Pharma Appoints James Sapirstein, Biopharma Industry Leader with Extensive Antiviral Development Experience, as Chief Executive Officer

June 3, 2026

Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza

May 26, 2026

Cocrystal Pharma Provides Business Update and Reports First Quarter 2026 Financial Results

May 14, 2026

COCP: Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Prevention

April 7, 2026

Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive

April 1, 2026

Cocrystal Pharma Reports 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

March 30, 2026

First Subjects Dosed in Cocrystal Pharma’s Phase 1b Study Evaluating CDI-988 for Norovirus Prevention and Treatment

March 8, 2026

COCP: CDI-988 Data to be Presented at ICAR 2026

February 23, 2026

Cocrystal Pharma’s First Oral Norovirus Protease Inhibitor CDI-988 to be Featured at the International Society for Antiviral Research Conference (ICAR) 2026

February 18, 2026

Decks in 2026